Evidence map›Paper›PMID 40166569›Full record

ArticlemedRxiv : the preprint server for health sciences2025

A mechanistic neural network model predicts both potency and toxicity of antimicrobial combination therapies.

Harkirat Singh Arora, Katherine Lev, Aaron Robida, Ramraj Velmurugan, Sriram Chandrasekaran

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Harkirat Singh AroraDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, US, 48105.
Katherine LevProgram in Chemical Biology, University of Michigan, Ann Arbor, MI, US, 48105.
Aaron RobidaCenter for Chemical Genomics, University of Michigan, Ann Arbor, MI, US, 48105.
Ramraj VelmuruganKomodo Health Inc., San Francisco, CA, US, 94105.
Sriram ChandrasekaranDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, US, 48105.ORCID 0000-0002-8405-5708

Funding

A multifactorial pipeline to dissect combinatorial drug efficacy in TuberculosisR01AI150826 · NIAID · UNIVERSITY OF WASHINGTON · PI SHERMAN, DAVID R · 2021 to 2024
$2.9M
Cellular Biotechnology Training Program (CBTP) - Years 31-35T32GM145304 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Guizhi Zhu · 2022 to 2026
$2.6M
Linking metabolic activity with drug sensitivity using metabolic influence networksR35GM137795 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Sriram Chandrasekaran · 2020 to 2026
$2.6M
NIAID NIH HHS R01 AI150826NIGMS NIH HHS R35 GM137795NIGMS NIH HHS T32 GM145304
6 · The paper itself

Abstract

Antimicrobial resistance poses a major global threat due to the diminishing efficacy of current treatments and limited new therapies. Combination therapy with existing drugs offers a promising solution, yet current empirical methods often lead to suboptimal efficacy and inadvertent toxicity. The high cost of experimentally testing numerous combinations underscores the need for data-driven methods to streamline treatment design. We introduce CALMA, an approach that predicts the potency and toxicity of multi-drug combinations in

Identifiers

PMID40166569
PMCPMC11957163

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.